The paradox of “great data, no funding.” You have the data. The models are working. Your preclinical package is strong. ✅ Clean PK PD ✅ A validated mechanism of action ✅ Consistent dose curves ✅ Promising in vivo results Biotech founders reach this point and expect momentum. But instead, investor meetings stall. Because no matter how strong the science looks, biotech investors keep asking the same uncomfortable questions: 👉 “What’s the actual market here?” 👉 “How urgent i